| 引用本文: | 王日相,吴爱祥,沈毅.舌下含服免疫治疗对变应性鼻炎患儿的临床疗效[J].中国现代应用药学,2020,37(8):981-985. |
| WANG Rixiang,WU Aixiang,SHEN Yi.Clinical Efficacy of Sublingual Immunotherapy on Children with Allergic Rhinitis[J].Chin J Mod Appl Pharm(中国现代应用药学),2020,37(8):981-985. |
|
| 摘要: |
| 目的 探讨粉尘螨滴剂舌下含服特异性免疫治疗（sublingual immunotherapy，SLIT）对变应性鼻炎（allergic rhinitis，AR）患儿血清sIgG4、IL-10和IL-33表达水平的作用，并对SLIT的临床疗效进行评估。方法 在2016年2月-2016年8月，宁波市医疗中心李惠利医院入组了70例AR患儿，将这些患儿随机分为SLIT试验组（SLIT配合对症药物）和药物对照组（仅对症药物），每组各35例患儿。分别在治疗前、治疗半年、治疗1年、治疗2年时，通过酶联免疫吸附法测定血清sIgG4、IL-10和IL-33的表达水平，同时对患儿的总鼻部症状评分（total nasal symptoms score，TNSS）和总用药评分（total medication score，TMS）进行评估。结果 经过2年的治疗后，与药物对照组相比，SLIT试验组的TNSS评分和TMS评分显著降低（P<0.01）。与治疗前相比，AR患儿经过2年的免疫治疗后，SLIT组的sIgG4和IL-10的水平显著上升（P<0.05），而IL-33的水平显著下降（P<0.05）。2年治疗后药物对照组的sIgG4、IL-10和IL-33的水平都未发生明显的改变。2年治疗结束时2组的sIgG4、IL-10和IL-33水平存在明显的差异（P<0.05）。结论 标准化粉尘螨滴剂SLIT对尘螨引起的儿童AR具有疗效，并且血清sIgG4、IL-10和IL-33表达水平的变化可能作为评估SLIT疗效的指标。 |
| 关键词: 变应性鼻炎 舌下含服特异性免疫治疗 血清sIgG4 白细胞介素-10 白细胞介素-33 |
| DOI：10.13748/j.cnki.issn1007-7693.2020.08.017 |
| 分类号:R969.4 |
| 基金项目:国家自然科学基金项目（81670920）；浙江省医药卫生科技计划项目（2020RC107）；宁波市科技项目（2018A610363） |
|
| Clinical Efficacy of Sublingual Immunotherapy on Children with Allergic Rhinitis |
|
WANG Rixiang1, WU Aixiang2, SHEN Yi3
|
|
1.Ningbo Medical Center of Lihuili Hospital, Department of Pharmacy, Ningbo 315041, China;2.Department of Pharmacy, Yinzhou People's Hospital, Ningbo 315040, China;3.Ningbo Medical Center of Lihuili Hospital, Department of Otolaryngology Head and Neck Surgery, Ningbo 315041, China
|
| Abstract: |
| OBJECTIVE To explore the effect of sublingual immunotherapy(SLIT) with standardized dermatophagoides farinae drops on serum sIgG4, IL-10 and IL-33 levels and evaluate the clinical efficacy of SLIT for the treatment of allergic rhinitis(AR) in children. METHODS Seventy children patients with dust-mite AR collected from Ningbo Medical Center of Lihuili Hospital between February and August 2016 were randomly assigned to SLIT group(SLIT combined with pharmacotherapy, n=35) and control group(only pharmacotherapy, n=35). Serum levels of sIgG4, IL-10 and IL-33 were measured by ELISA before and after SLIT for 6 months, 1 year and 2 years, total nasal symptoms score(TNSS) and total medication score(TMS) were evaluated. RESULTS TNSS and TMS scores of SLIT group was significantly lower than the control group after 2 years' treatment(P<0.01). Compared with before treatment, the levels of sIgG4 and IL-10 increased significantly and IL-33 decreased significantly in children with AR after 2 years' SLIT(P<0.05). The level of sIgG4, IL-10 and IL-33 in control group did not differ significantly before and after 2 years' treatment. Meanwhile, a significant difference was found in the expression of sIgG, IL-10 and IL-33 between two groups at the end of 2 years' treatment(P<0.05). CONCLUSION SLIT with dermatophagoides farinae drops is efficient treatment for children with HDM-induced AR. The change of serum sIgG4, IL-10 and IL-33 level may be used as an indicator to assess the clinical efficacy of SLIT. |
| Key words: allergic rhinitis sublingual immunotherapy serum sIgG4 interleukin-10(IL-10) interleukin-33(IL-33) |
